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WHO classification for tumors of the central nervous system strongly endorses 
molecular tests for the precise diagnosis of diffuse gliomas. Subclassification of isocitrate 
dehydrogenase (IDH)-mutant gliomas into IDH-mutant astrocytomas and oligodendrogliomas 
requires testing for complete 1p/19q co-deletion [1] in those cases not showing loss of ATRX 
expression [2]. 
Epigenetics recently emerged as a promising new avenue for the classification of 
gliomas and driver mutations in epigenetic regulators like IDH1/2 and H3F3A are present in 
gliomas and are characteristic for distinct subtypes [3]. Comparison of methylation profiles 
generated by chip analysis has been shown to be a powerful tool to distinguish between brain 
tumor entities [4]. In addition to DNA methylation, post-translational modifications (PTMs) at 
histone proteins form the basis of epigenetic regulation.  
Despite progress into classification substantial limitations for diagnosis remain, e.g. 
valid 1p/19q testing requires array technologies or next-generation-sequencing approaches. 
Furthermore, while alterations in the DNA methylation status of gliomas are already well 
documented, changes to the epigenetic layer at the level of histone modifications are only 
poorly characterised.  
The role of H3K27 tri-methylation in several brain tumor entities is well established [5-
8]. We assessed H3K27me3 by immunohistochemistry in a series of 118 IDH-mutant 
oligodendrogliomas and astrocytomas classified by DNA methylation profiling including 
1p/19q status determination (Figure 1a, Supplementary table 1). We used two of the most 
widely applied antibodies, which consistently showed tumor cell-specific reduction in DMG-
H3K27M, EPN_PFA and PRC2 inactivated MPNST [5-8]. We found that these two 
H3K27me3 antibodies generated strikingly different staining patterns: while the polyclonal 
antibody (07–449, Millipore) shows retained H3K27me3 in all samples analysed (10/10 
oligodendrogliomas and 10/10 astrocytomas), the monoclonal C36B11 antibody shows a 
complete loss of nuclear staining in almost all oligodendrogliomas (loss in 74/76, 97%) while 
astrocytomas showed retained expression in the vast majority of cases (loss in 7/42, 17%). 
Using clone C36B11 similar results were recently reported in an independent study [9]. 
In order to get an antibody-independent and more quantitative insight we applied a 
recently developed data-independent acquisition (DIA) - mass spectrometry method to 
determine the H3K27 methylation status. The H3K27me3-levels of 12 measured 
oligodendroglioma samples were on average 2-fold lower compared with 14 astrocytoma 
samples (Figure 1B). While oligodendrogliomas showed a mean fraction of 4.6 % H3K27me3, 
the astroglioma samples had 10.4 % of H3K27me3. A similar 2-fold difference was found for 
the H3.3K27me3 mark at the histone isoform H3.3 (H3.3K27me3: 2.7 % vs 6 %). Of note, to 
ensure high specificity, all histone mass spectrometric measurements were established and 
calibrated with synthetic reference peptides harboring the modification of interest. In summary, 
highly specific mass spectrometry measurements confirmed the lower levels of H3K27me3 in 
oligodendrogliomas.  
In addition to single methylation sites, mass spectrometry-based quantification of 
protein modifications also allows determination of complex combinatorial modification 
patterns, aka histone modification motifs [10, 11]. From the 38 differently modified histone 
motifs encompassing all possible combinations of mono-, di- and tri-methylation on H3K27 
and H3K36, as well as acetylation on H3K27, five modification motifs showed more than 2-
fold differences between the oligodendroglioma and astrocytoma samples (Supplementary 
Figure 1a).  
We next generated a comprehensive histone epi-proteomic map that documents the 
abundance of almost all characterized and many uncharacterized histone modifications at the 
five major histone proteins (Figures 1c, Supplementary Figure 1b). The DIA – mass 
spectrometry protocol recorded all possible peptide signatures and allowed extraction of these 
signals after so called “targeted assays” had been established, a procedure that connects a mass 
spectrometry signal with the peptide of interest by using spectra from a library of synthetic 
reference peptides as ground truth. We generated a DIA library of over 300 histone peptides 
that contain 17 different modification types. Across the 26 samples, we consistently detected 
and quantified 144 histone peptides. Among them were lysine acetylations and methylations at 
17 different histone sequence isoforms, phosphorylation and butyrylations at histone H3, 
propionylation at histone H4 and ubiquitylations at histones H3 and H2A (Supplementary 
Figure 1b, Supplementary table 2). 45 histone peptides were significantly different between the 
oligodendroglioma and astrocytoma samples (p < 0.05, FDR-adjusted p-values after performing 
2-sided unpaired t-test). In addition to H3/H3.3K27me3, another repressive mark (H3 
K9me3K14ac) was depleted in oligodendrogliomas. Oligodendrogliomas also showed an 
enrichment of acetylated lysine 9 at histone H2AX (H2AXK9ac) and ubiquitylated lysine 15 
on H2AJ (H2AJ K13ac K15ub), two poorly-characterised histone modifications that have been 
linked to DNA damage repair [12, 13]. Most of the oligodendroglioma samples also showed 
higher levels of butyrylated lysine 18 on H3 (H3K18bu), which is a yet to be characterised 
histone modification type.  
An unbiased unsupervised clustering analysis using all 144 quantified peptides 
separated the two IDH-mutant glioma subtypes in full accordance to the EPIC DNA 
methylation classifier and the 1p/19q status (Figure 1c and Supplementary Figure 1c). 
Restricting the clustering analysis to the 45 significantly different histone peptides further 
increased the correlations within the groups of oligodendrogliomas and astrocytomas. The 
clustering also revealed at least two histone epi-proteomic subgroups of oligodendroglioma, a 
feature not observable in the DNA methylation dataset (Figure 1c). These oligodendroglioma 
subgroups vary in a number of histone peptides, including the active marks H3K36me1 and 
H3K36me2. Of note, the separation of astrocytomas and oligodendrogliomas was less apparent 
when we used the 46 histone peptides that are commonly reported in histone mass spectrometry 
analysis (Supplementary Figures 1c). Furthermore, we noted that while most individual histone 
modifications show only moderate differences between the two glioma subtypes, the 
combination of multiple such histone motifs increases the discriminatory power to differentiate 
oligodendroglioma from astrocytoma. 
In summary, so far a comprehensive analysis of the histone epi-proteome of brain 
tumors was lacking. By applying a DIA-based mass spectrometry method, our results indicate 
that histone epi-proteomic profiling at the depth of the current method has the capacity to 
identify clinically-relevant glioma sub-groups. Our analysis documented significant abundance 
differences in almost one-third of the 144 quantified histone peptides. This study therefore 
provides the first evidence for a substantial differential alteration of the histone epi-proteome 
in IDH-mutant glioma subtypes suggesting that 1p/19q co-deletion status may interfere with 
epigenetic modifications as well. In addition to being of potential use for diagnostic purposes 
(supplementary note), this could also provide novel insights in glioma biology and may identify 
new therapeutic targets.  
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Figure legend 
Fig. 1a: H3K27me3 immunohistochemistry. Antibody C36B11 (upper left) and antibody 07–
449 (bottom left) show retained expression in astrocytoma. Antibody C36B11 shows tumor cell 
specific lack of nuclear expression in oligodendroglioma (upper right) while antibody 07–449 
shows retained expression in the same oligodendroglioma (bottom right). Scale bar = 200µm 
b: Oligodendrogliomas have significantly lower H3K27 tri-methylation (H3K27me3) than 
astrocytomas (p < 0.05, FDR-adjusted p-values after performing 2-sided unpaired t-test). Box 
plot analysis comparing tri-methylation at lysine 27 between oligodendrogliomas and 
astrocytomas at the canonical histone H3.1/H3.2 (top panel) and the histone variant H3.3 
(bottom panel). Values correspond to the estimated fraction of methylation on the ArgC-like 
peptide ranging from lysine 27 to arginine 40. c: Unsupervised hierarchical clustering 
analysis separates oligodendrogliomas from astrocytomas. Clustering was performed on a 
pairwise Spearman correlation matrix using the standard setting in the R package “heatmap.2”, 
i.e. the “complete” method. Cutting the dendrogram at the second level generates two clusters 
of the oligodendroglioma dataset and one cluster in the astrocytoma dataset. Sample 
descriptions are shown above the heat map (sex, age, WHO status, histology, DNA methylome 
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